A Phase 3 interventional study of alpelisib and placebo in Triple Negative Breast Neoplasms, sponsored by Novartis Pharmaceuticals. Terminated at 78 sites in 30 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Triple Negative Breast Neoplasms by Novartis — 4 open to participants now, 6 under way, none of them phase 3. Triple Negative Breast Neoplasms · Novartis.
Among the 22 studies in Triple Negative Breast Neoplasms by Novartis, this one is the 11th largest by enrollment, is the only one that started in 2020, is the only one in phase 3, and was the 16th registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →4 of the 22 studies in Triple Negative Breast Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Australia, Japan
Ages 18+
Novartis Pharmaceuticals · Sites in Denmark, Japan
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Canada, Denmark and 4 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Belgium, Canada and 7 more countries
Ages 18–100
By country, each count listing its studies:
Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 7 · Phase 3 1
First in 2010; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 137 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 132 across the 22 interventional studies. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
2 of the studies in Triple Negative Breast Neoplasms by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03891953Novartis PharmaceuticalsStudy of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | 2027-06-25 |
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Triple Negative Breast Neoplasms by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss (Study Part B1) or PTEN loss without PIK3CA mutation (Study Part B2)
The recruitment of Part A was halted on 11-Nov-2022 due to slow recruitment. Since Part B1 did not meet its primary objective for confirmed overall response rate, the Part B2 was not initiated, and the recruitment was halted for the entire study.
Upon confirming either PIK3CA mutation and/or PTEN loss status, advanced TNBC participants meeting all other eligibility criteria were assigned to either Part A (PIK3CA mutation regardless of PTEN loss) or Part B1 (PTEN loss with PIK3CA unknown or non-mutant).
In Part A, participants were randomized a 1:1 to receive either:
In Part B1, participants received alpelisib 300 mg daily orally + nab-paclitaxel 100 mg/m\^2 IV on Days 1, 8, and 15 of each 28-day cycle.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received alpelisib 300 mg orally + nab-paclitaxel 100 mg/m\^2 intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle
Drug: alpelisib · Drug: nab-paclitaxel
Participants received placebo + nab-paclitaxel 100 mg/m\^2 IV on Days 1, 8, and 15 of each 28-day cycle.
Drug: placebo · Drug: nab-paclitaxel
Participants received alpelisib 300 mg orally + nab-paclitaxel 100 mg/m\^2 IV on Days 1, 8, and 15 of each 28-day cycle.
Drug: alpelisib · Drug: nab-paclitaxel
300 mg orally, once per day (QD), tablets
Also known as: BYL719
300 mg orally, once per day (QD), tablets
Also known as: alpelisib-matching placebo
100 mg/m\^2 IV infusion, once per day (QD)
Also known as: abraxane
Progression-free Survival (PFS) Per Investigator Assessment in Study Part A
PFS was defined as time from the date of randomization to the date of the first documented progressive disease (PD) or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. PD=At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm\^2. PFS was censored at the date of the last adequate tumor assessment, if no PFS event was observed prior to the analysis cut-off date.
Time frame: Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months
Overall Response Rate (ORR) Based on Local Radiology Assessments in Participants With Measurable Disease at Baseline in Study Part B1
ORR was defined as the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1. BOR was defined as the best response recorded from the start of the study treatment until progressive disease (PD)/recurrence. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters; PD= At least a 20% increase in the sum of diameters of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Up to 6 months
Overall Survival in Study Part A
Overall survival is defined as the time from date of randomization to date of death due to any cause.
Time frame: Up to 66 months
Overall Response Rate (ORR) With Confirmed Response in Study Part A
ORR with confirmed response was the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), as per local review and according to RECIST 1.1. BOR was defined as the best response recorded from the start of the study treatment until progressive disease (PD)/recurrence. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters; PD= At least a 20% increase in the sum of diameters of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months
Clinical Benefit Rate (CBR) With Confirmed Response in Study Part A
Clinical benefit rate (CBR) was defined as the percentage of participants with a best overall response of complete response (CR), or partial response (PR) or an overall lesion response of stable disease (SD), lasting as per local review, for a duration of at least 24 weeks. CR, PR and SD are defined according to RECIST 1.1 based on investigator's assessment. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.
Time frame: Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months
Clinical Benefit Rate (CBR) With Confirmed Response in Study Part B1
Clinical benefit rate (CBR) was defined as the percentage of participants with a best overall response of complete response (CR), or partial response (PR) or an overall lesion response of stable disease (SD), lasting as per local review, for a duration of at least 24 weeks. CR, PR and SD are defined according to RECIST 1.1 based on investigator's assessment. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.
Time frame: Up to 6 months
Time to Response (TTR) in Study Part A
Time to response (TTR) was defined as the time from the date of randomization/enrolment to the first documented response of either complete response (CR) or partial response (PR), which must be subsequently confirmed (although date of initial response is used, not date of confirmation). CR and PR were based on tumor response data as per local review and according to RECIST 1.1. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters.
Time frame: Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months
Time to Response (TTR) in Study Part B1
Time to response (TTR) was defined as the time from the date of randomization/enrolment to the first documented response of either complete response (CR) or partial response (PR), which must be subsequently confirmed (although date of initial response was used, not date of confirmation). CR and PR were based on tumor response data as per local review and according to RECIST 1.1. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters.
Time frame: Up to 6 months
Duration of Response (DOR) With Confirmed Response in Study Part A
Duration of response (DOR) with confirmed response only applied to participants whose best overall response (BOR) was confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 based on tumor response data per local review. The start date was the date of first documented response of CR or PR (i.e. the start date of response, not the date when response was confirmed), and the end date was defined as the date of the first documented progressive disease (PD) or death due to underlying cancer. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters.
Time frame: Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months
Duration of Response (DOR) With Confirmed Response in Study Part B1
Duration of response (DOR) with confirmed response only applied to participants whose best overall response (BOR) was confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 based on tumor response data per local review. The start date was the date of first documented response of CR or PR (i.e. the start date of response, not the date when response was confirmed), and the end date was defined as the date of the first documented progressive disease (PD) or death due to underlying cancer. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters.
Time frame: Up to approximately 20 months
Overall Survival in Study Part B1
Overall survival for Part B1 was defined as the number of participants who were alive at the end of the post-treatment period.
Time frame: Up to approximately 26 months.
Progression-free Survival (PFS) Per Investigator Assessment in Study Part B1
PFS was defined as time from the date of enrolment to the date of the first documented progressive disease (PD) or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. PD=At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm\^2. PFS was censored at the date of the last adequate tumor assessment, if no PFS event was observed prior to the analysis cut-off date.
Time frame: Up to 6 months
PFS Based on Local Radiology Assessments Using RECIST 1.1 Criteria for Participants by PIK3CA Mutation Status Measured in Baseline Circulating Tumor Deoxyribonucleic Acid (ctDNA) in Study Part A
PFS in participants with PIK3CA mutation as measured in ctDNA. PFS was defined as time from the date of randomization to the date of the first documented progression or death due to any cause.
Time frame: Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months
Post-Hoc: All Collected Deaths
On-treatment deaths due to any cause were collected from first dose of study medication to 30 days after the last dose of study treatment. Post-treatment survival follow-up deaths were collected from Day 31 after last dose of study medication to the data cut-off date.
Time frame: On-treatment deaths: Up to approximately 28 months (Part A) or approximately 17 months (Part B1). Post-treatment survival follow-up deaths: Up to approximately 7 additional months (Part A) or approximately 9 additional months (Part B1).
| Milestone | Part A: Alpelisib + Nab-paclitaxel | Part A: Placebo + Nab-paclitaxel | Part B1: Alpelisib + Nab-paclitaxel |
|---|---|---|---|
| Started | 52 | 50 | 35 |
| Completed | 8 | 14 | 4 |
| Not completed | 44 | 36 | 31 |
| Withdrew: Progressive disease | 33 | 29 | 22 |
| Withdrew: Death | 5 | 1 | 3 |
| Withdrew: Physician decision | 3 | 2 | 4 |
| Withdrew: Participant decision | 1 | 3 | 1 |
| Withdrew: Adverse event | 2 | 1 | 1 |
PFS was defined as time from the date of randomization to the date of the first documented progressive disease (PD) or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. PD=At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm\^2. PFS was censored at the date of the last adequate tumor assessment, if no PFS event was observed prior to the analysis cut-off date.
| months | Part A: Alpelisib + Nab-paclitaxel | Part A: Placebo + Nab-paclitaxel |
|---|---|---|
| Progression-free Survival (PFS) Per Investigator Assessment in Study Part A | 7.2 (3.71 to 8.57) | 5.6 (3.75 to 12.68) |
ORR was defined as the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1. BOR was defined as the best response recorded from the start of the study treatment until progressive disease (PD)/recurrence. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters; PD= At least a 20% increase in the sum of diameters of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, the sum must also demonstrate an absolute increase of at least 5 mm.
| percentage of participants | Part B1: Alpelisib + Nab-paclitaxel |
|---|---|
| Overall Response Rate (ORR) Based on Local Radiology Assessments in Participants With Measurable Disease at Baseline in Study Part B1 | 14.3 (4.8 to 30.3) |
Overall survival is defined as the time from date of randomization to date of death due to any cause.
Results for this outcome have not been posted.
ORR with confirmed response was the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), as per local review and according to RECIST 1.1. BOR was defined as the best response recorded from the start of the study treatment until progressive disease (PD)/recurrence. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters; PD= At least a 20% increase in the sum of diameters of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, the sum must also demonstrate an absolute increase of at least 5 mm.
| percentage of participants | Part A: Alpelisib + Nab-paclitaxel | Part A: Placebo + Nab-paclitaxel |
|---|---|---|
| Overall Response Rate (ORR) With Confirmed Response in Study Part A | 40.4 (27.0 to 54.9) | 34.0 (21.2 to 48.8) |
Clinical benefit rate (CBR) was defined as the percentage of participants with a best overall response of complete response (CR), or partial response (PR) or an overall lesion response of stable disease (SD), lasting as per local review, for a duration of at least 24 weeks. CR, PR and SD are defined according to RECIST 1.1 based on investigator's assessment. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.
| percentage of participants | Part A: Alpelisib + Nab-paclitaxel | Part A: Placebo + Nab-paclitaxel |
|---|---|---|
| Clinical Benefit Rate (CBR) With Confirmed Response in Study Part A | 50.0 (35.8 to 64.2) | 44.0 (30.0 to 58.7) |
Clinical benefit rate (CBR) was defined as the percentage of participants with a best overall response of complete response (CR), or partial response (PR) or an overall lesion response of stable disease (SD), lasting as per local review, for a duration of at least 24 weeks. CR, PR and SD are defined according to RECIST 1.1 based on investigator's assessment. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.
| percentage of participants | Part B1: Alpelisib + Nab-paclitaxel |
|---|---|
| Clinical Benefit Rate (CBR) With Confirmed Response in Study Part B1 | 25.7 (12.5 to 43.3) |
Time to response (TTR) was defined as the time from the date of randomization/enrolment to the first documented response of either complete response (CR) or partial response (PR), which must be subsequently confirmed (although date of initial response is used, not date of confirmation). CR and PR were based on tumor response data as per local review and according to RECIST 1.1. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters.
| months | Part A: Alpelisib + Nab-paclitaxel | Part A: Placebo + Nab-paclitaxel |
|---|---|---|
| Time to Response (TTR) in Study Part A | NA (4.14 to NA) | NA (NA to NA) |
Time to response (TTR) was defined as the time from the date of randomization/enrolment to the first documented response of either complete response (CR) or partial response (PR), which must be subsequently confirmed (although date of initial response was used, not date of confirmation). CR and PR were based on tumor response data as per local review and according to RECIST 1.1. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters.
| months | Part B1: Alpelisib + Nab-paclitaxel |
|---|---|
| Time to Response (TTR) in Study Part B1 | NA (NA to NA) |
Duration of response (DOR) with confirmed response only applied to participants whose best overall response (BOR) was confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 based on tumor response data per local review. The start date was the date of first documented response of CR or PR (i.e. the start date of response, not the date when response was confirmed), and the end date was defined as the date of the first documented progressive disease (PD) or death due to underlying cancer. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters.
| months | Part A: Alpelisib + Nab-paclitaxel | Part A: Placebo + Nab-paclitaxel |
|---|---|---|
| Duration of Response (DOR) With Confirmed Response in Study Part A | 7.39 (5.59 to 9.53) | NA (10.55 to NA) |
Duration of response (DOR) with confirmed response only applied to participants whose best overall response (BOR) was confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 based on tumor response data per local review. The start date was the date of first documented response of CR or PR (i.e. the start date of response, not the date when response was confirmed), and the end date was defined as the date of the first documented progressive disease (PD) or death due to underlying cancer. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters.
| months | Part B1: Alpelisib + Nab-paclitaxel |
|---|---|
| Duration of Response (DOR) With Confirmed Response in Study Part B1 | 11.04 (7.46 to NA) |
Overall survival for Part B1 was defined as the number of participants who were alive at the end of the post-treatment period.
| Participants | Part B1: Alpelisib + Nab-paclitaxelEdit |
|---|---|
| Overall Survival in Study Part B1 | 21 |
PFS was defined as time from the date of enrolment to the date of the first documented progressive disease (PD) or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. PD=At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm\^2. PFS was censored at the date of the last adequate tumor assessment, if no PFS event was observed prior to the analysis cut-off date.
| months | Part B1: Alpelisib + Nab-paclitaxel |
|---|---|
| Progression-free Survival (PFS) Per Investigator Assessment in Study Part B1 | 3.71 (3.15 to 5.88) |
PFS in participants with PIK3CA mutation as measured in ctDNA. PFS was defined as time from the date of randomization to the date of the first documented progression or death due to any cause.
| months | Part A: Alpelisib + Nab-paclitaxel | Part A: Placebo + Nab-paclitaxel |
|---|---|---|
| PFS Based on Local Radiology Assessments Using RECIST 1.1 Criteria for Participants by PIK3CA Mutation Status Measured in Baseline Circulating Tumor Deoxyribonucleic Acid (ctDNA) in Study Part A | 7.5 (3.58 to 9.17) | 3.5 (1.77 to 5.85) |
On-treatment deaths due to any cause were collected from first dose of study medication to 30 days after the last dose of study treatment. Post-treatment survival follow-up deaths were collected from Day 31 after last dose of study medication to the data cut-off date.
| Participants | Part A: Alpelisib + Nab-paclitaxel | Part A: Placebo + Nab-paclitaxel | Part B1: Alpelisib + Nab-paclitaxelEdit |
|---|---|---|---|
| On-treatment deaths | 6 | 6 | 3 |
| Post-treatment survival follow-up deaths | 19 | 14 | 11 |
| All deaths | 25 | 20 | 14 |
Collected over Adverse events were collected up to approximately 28 months (Part A) or up to approximately 17 months (Part B1). Deaths were collected in the post-treatment survival follow-up from 31 days after last dose of study medication until the data cut-off date, up to approximately 7 additional months (Part A) or approximately 9 additional months (Part B1). These were not considered AEs.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Alpelisib + Nab-paclitaxelEdit | 6/52 (11.5%) | 22/52 (42.3%) | 51/52 (98.1%) |
| Part A: Placebo + Nab-paclitaxelEdit | 6/50 (12%) | 15/50 (30%) | 47/50 (94%) |
| Part B1: Alpelisib + Nab-paclitaxelEdit | 3/35 (8.6%) | 14/35 (40%) | 34/35 (97.1%) |
| Part A: Alpelisib + Nab-paclitaxel (Post-treatment Survival Follow-up) | 19/46 (41.3%) | — | — |
| Part A: Placebo + Nab-paclitaxel (Post-treatment Survival Follow-up) | 14/44 (31.8%) | — | — |
| Part B1: Alpelisib + Nab-paclitaxel (Post-treatment Survival Follow-up) | 11/32 (34.4%) | — | — |
| Event | Part A: Alpelisib + Nab-paclitaxelEdit | Part A: Placebo + Nab-paclitaxelEdit | Part B1: Alpelisib + Nab-paclitaxelEdit | Part A: Alpelisib + Nab-paclitaxel (Post-treatment Survival Follow-up) | Part A: Placebo + Nab-paclitaxel (Post-treatment Survival Follow-up) | Part B1: Alpelisib + Nab-paclitaxel (Post-treatment Survival Follow-up) |
|---|---|---|---|---|---|---|
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 4/52 | 1/50 | 1/35 | — | — | — |
| StomatitisGastrointestinal disorders | 3/52 | 0/50 | 0/35 | — | — | — |
| DiarrhoeaGastrointestinal disorders | 1/52 | 0/50 | 2/35 | — | — | — |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/52 | 2/50 | 0/35 | — | — | — |
| PyrexiaGeneral disorders | 2/52 | 1/50 | 0/35 | — | — | — |
| PneumoniaInfections and infestations | 2/52 | 0/50 | 1/35 | — | — | — |
| HyperglycaemiaMetabolism and nutrition disorders | 2/52 | 0/50 | 0/35 | — | — | — |
| Back painMusculoskeletal and connective tissue disorders | 2/52 | 1/50 | 1/35 | — | — | — |
| Abdominal painGastrointestinal disorders | 0/52 | 0/50 | 1/35 | — | — | — |
| HaemorrhoidsGastrointestinal disorders | 1/52 | 0/50 | 1/35 | — | — | — |
| Event | Part A: Alpelisib + Nab-paclitaxelEdit | Part A: Placebo + Nab-paclitaxelEdit | Part B1: Alpelisib + Nab-paclitaxelEdit | Part A: Alpelisib + Nab-paclitaxel (Post-treatment Survival Follow-up) | Part A: Placebo + Nab-paclitaxel (Post-treatment Survival Follow-up) | Part B1: Alpelisib + Nab-paclitaxel (Post-treatment Survival Follow-up) |
|---|---|---|---|---|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 38/52 | 8/50 | 19/35 | — | — | — |
| DiarrhoeaGastrointestinal disorders | 33/52 | 11/50 | 21/35 | — | — | — |
| NauseaGastrointestinal disorders | 20/52 | 12/50 | 17/35 | — | — | — |
| AnaemiaBlood and lymphatic system disorders | 25/52 | 22/50 | 11/35 | — | — | — |
| Weight decreasedInvestigations | 24/52 | 5/50 | 13/35 | — | — | — |
| AlopeciaSkin and subcutaneous tissue disorders | 13/52 | 14/50 | 8/35 | — | — | — |
| NeutropeniaBlood and lymphatic system disorders | 10/52 | 13/50 | 8/35 | — | — | — |
| RashSkin and subcutaneous tissue disorders | 13/52 | 13/50 | 3/35 | — | — | — |
| FatigueGeneral disorders | 12/52 | 10/50 | 9/35 | — | — | — |
| StomatitisGastrointestinal disorders | 13/52 | 2/50 | 7/35 | — | — | — |
| Age, Continuous(years) | Part A: Alpelisib + Nab-paclitaxel | Part A: Placebo + Nab-paclitaxel | Part B1: Alpelisib + Nab-paclitaxel | Total |
|---|---|---|---|---|
| Mean | 56.8 ± 9.76 | 59.1 ± 11.34 | 48.4 ± 12.21 | 55.5 ± 11.74 |
| Sex: Female, Male(Participants) | Part A: Alpelisib + Nab-paclitaxel | Part A: Placebo + Nab-paclitaxel | Part B1: Alpelisib + Nab-paclitaxel | Total |
|---|---|---|---|---|
| Female | 52 | 49 | 35 | 136 |
| Male | 0 | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Part A: Alpelisib + Nab-paclitaxel | Part A: Placebo + Nab-paclitaxel | Part B1: Alpelisib + Nab-paclitaxel | Total |
|---|---|---|---|---|
| White | 32 | 30 | 23 | 85 |
| Asian | 17 | 19 | 10 | 46 |
| Multiple | 1 | 1 | 0 | 2 |
| Black Or African American | 1 | 0 | 1 | 2 |
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Unknown | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Jun 2020 to primary completion in May 2023, 35 months.
Results were first posted in Jul 2024, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpelisib
Triple Negative Breast Neoplasms →